Furthermore, it has been recently shown that AML with TP53 mutations are associated with an infiltration of cytotoxic lymphocytes in the tumor microenvironment, indicating that immune intervention could be of value in this subgroup of patients [100, 101]. Here, TP53 is linked to acute myeloid leukemia.